Barclays’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-57,000
| Closed | -$1.78M | – | 5040 |
|
|
2023
Q4 | $1.78M | Buy |
+57,000
| New | +$1.36M | ﹤0.01% | 3005 |
|
|
2021
Q2 | – | Sell |
-500
| Closed | -$13K | – | 4851 |
|
|
2021
Q1 | $13K | Buy |
+500
| New | +$22K | ﹤0.01% | 4412 |
|
|
2020
Q2 | – | Sell |
-46,800
| Closed | -$1.98M | – | 5485 |
|
|
2020
Q1 | $1.98M | Sell |
46,800
-33,400
| -42% | -$1.38M | ﹤0.01% | 2295 |
|
|
2019
Q4 | $3.43M | Buy |
80,200
+33,300
| +71% | +$1.45M | ﹤0.01% | 2422 |
|
|
2019
Q3 | $1.69M | Sell |
46,900
-306,300
| -87% | -$9.29M | ﹤0.01% | 3077 |
|
|
2019
Q2 | $9.44M | Buy |
353,200
+189,200
| +115% | +$4.83M | 0.01% | 1394 |
|
|
2019
Q1 | $4.4M | Sell |
164,000
-215,500
| -57% | -$5.03M | ﹤0.01% | 1755 |
|
|
2018
Q4 | $6.14M | Sell |
379,500
-291,000
| -43% | -$5.65M | ﹤0.01% | 1461 |
|
|
2018
Q3 | $13.9M | Buy |
670,500
+516,600
| +336% | +$8.13M | 0.01% | 1056 |
|
|
2018
Q2 | $2.35M | Buy |
153,900
+41,200
| +37% | +$735K | ﹤0.01% | 2422 |
|
|
2018
Q1 | $2.53M | Buy |
112,700
+18,800
| +20% | +$521K | ﹤0.01% | 2249 |
|
|
2017
Q4 | $2.83M | Sell |
93,900
-81,200
| -46% | -$2.6M | ﹤0.01% | 2122 |
|
|
2017
Q3 | $6.6M | Sell |
175,100
-11,700
| -6% | -$381K | 0.01% | 1324 |
|
|
2017
Q2 | $5.21M | Buy |
186,800
+121,900
| +188% | +$3.63M | 0.01% | 1441 |
|
|
2017
Q1 | $2.23M | Sell |
64,900
-173,900
| -73% | -$6.14M | ﹤0.01% | 1988 |
|
|
2016
Q4 | $6.89M | Buy |
238,800
+179,700
| +304% | +$4.75M | 0.01% | 1170 |
|
|
2016
Q3 | $1.88M | Buy |
59,100
+3,100
| +6% | +$105K | ﹤0.01% | 2054 |
|
|
2016
Q2 | $1.82M | Sell |
56,000
-378,200
| -87% | -$12.7M | ﹤0.01% | 2099 |
|
|
2016
Q1 | $11.7M | Buy |
434,200
+406,300
| +1,456% | +$8.86M | 0.02% | 688 |
|
|
2015
Q4 | $977K | Buy |
27,900
+5,400
| +24% | +$190K | ﹤0.01% | 2636 |
|
|
2015
Q3 | $743K | Buy |
22,500
+5,100
| +29% | +$212K | ﹤0.01% | 3003 |
|
|
2015
Q2 | $713K | Sell |
17,400
-44,300
| -72% | -$1.71M | ﹤0.01% | 3175 |
|
|
2015
Q1 | $1.97M | Sell |
61,700
-121,100
| -66% | -$4.16M | ﹤0.01% | 2330 |
|
|
2014
Q4 | $5.67M | Buy |
182,800
+39,000
| +27% | +$1.11M | 0.01% | 1590 |
|
|
2014
Q3 | $3.45M | Buy |
143,800
+61,300
| +74% | +$1.43M | ﹤0.01% | 2135 |
|
|
2014
Q2 | $1.81M | Buy |
82,500
+12,300
| +18% | +$257K | ﹤0.01% | 2706 |
|
|
2014
Q1 | $1.69M | Sell |
70,200
-113,000
| -62% | -$2.86M | ﹤0.01% | 2723 |
|
|
2013
Q4 | $4.4M | Buy |
183,200
+99,400
| +119% | +$2.35M | ﹤0.01% | 1936 |
|
|
2013
Q3 | $2.26M | Sell |
83,800
-19,400
| -19% | -$406K | ﹤0.01% | 2431 |
|
|
2013
Q2 | $1.87M | Buy |
+103,200
| New | +$1.42M | ﹤0.01% | 2614 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Barclays's ACAD Position: Q1 2026 in Review
Barclays reduced its Acadia Pharmaceuticals (ACAD) stake by 92% in Q1 2026, selling an estimated $8.14M and leaving 27,803 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.
Barclays first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.9M in Q3 2019. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Barclays held 27,803 shares of Acadia Pharmaceuticals worth $619K as of Q1 2026.
- Barclays sold 340,501 Acadia Pharmaceuticals shares in Q1 2026, an estimated $8.14M.
- Acadia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3060 holding.
- Barclays first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Acadia Pharmaceuticals position peaked at $10.9M in Q3 2019.
- 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.